NZ193011A
(en)
|
1979-03-19 |
1983-03-15 |
Ici Australia Ltd |
Diarylamine derivatives intermediates herbicidal compositions
|
US4670560A
(en)
|
1986-04-28 |
1987-06-02 |
Ortho Pharmaceutical Corporation |
Thienopyrimidine-2,4-dione derivatives and intermediates thereof
|
DE3880544D1
(de)
|
1987-04-21 |
1993-06-03 |
Basf Ag |
P-phenoxy-phenoxymethyl-fuenfring-heteroaromaten.
|
JPH02225485A
(ja)
|
1989-02-27 |
1990-09-07 |
Taiho Yakuhin Kogyo Kk |
チエノピリミジン―3―酢酸誘導体
|
JP3121061B2
(ja)
|
1991-10-04 |
2000-12-25 |
塩野義製薬株式会社 |
アルコキシイミノアセトアミド類製造用中間体の製造法およびそれに用いる中間体
|
DE4137940A1
(de)
|
1991-11-18 |
1993-05-19 |
Basf Ag |
3-isoxazolylphenylverbindungen, ihre herstellung und ihre verwendung
|
US5258551A
(en)
|
1991-12-18 |
1993-11-02 |
Shionogi & Co., Ltd. |
Process for producing α-ketoamide derivative
|
AU5891494A
(en)
|
1993-01-29 |
1994-08-15 |
Nippon Soda Co., Ltd. |
Heterocyclic derivative
|
WO1994024095A1
(en)
|
1993-04-16 |
1994-10-27 |
Abbott Laboratories |
Immunosuppressive agents
|
TW276256B
(pl)
|
1993-08-26 |
1996-05-21 |
Takeda Pharm Industry Co Ltd |
|
JP3811196B2
(ja)
|
1993-08-26 |
2006-08-16 |
武田薬品工業株式会社 |
エンドセリン拮抗剤、チエノピリミジン誘導体およびその製造法
|
IL112721A0
(en)
|
1994-03-10 |
1995-05-26 |
Zeneca Ltd |
Azole derivatives
|
US5854268A
(en)
|
1994-08-02 |
1998-12-29 |
Merck Sharp & Dohme, Ltd. |
Azetidine, pyrrolidine and piperidine derivatives
|
GB9501865D0
(en)
|
1995-01-31 |
1995-03-22 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5633272A
(en)
|
1995-02-13 |
1997-05-27 |
Talley; John J. |
Substituted isoxazoles for the treatment of inflammation
|
JPH09110873A
(ja)
|
1995-08-17 |
1997-04-28 |
Takeda Chem Ind Ltd |
チエノピリミジン誘導体、その製造法および用途
|
DE69624829T2
(de)
|
1995-08-17 |
2003-07-31 |
Takeda Chemical Industries, Ltd. |
Thienopyrimidinderivate als endothelin antagonisten
|
DE19536811A1
(de)
|
1995-10-02 |
1997-04-03 |
Basf Ag |
Zwischenprodukte und Verfahren zur Herstellung von substituierten Salicylsäurederivaten als Pflanzenschutzmittel
|
EP0880363B1
(en)
|
1996-02-13 |
2002-09-11 |
G.D. SEARLE & CO. |
Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a 4 hydrolase inhibitor
|
JP2007302703A
(ja)
|
1996-04-30 |
2007-11-22 |
Takeda Chem Ind Ltd |
医薬組成物
|
CA2250908C
(en)
|
1996-04-30 |
2012-03-13 |
Takeda Chemical Industries, Ltd. |
Combined use of gnrh agonist and antagonist
|
SE9702001D0
(sv)
|
1997-05-28 |
1997-05-28 |
Astra Pharma Prod |
Novel compounds
|
US6984644B2
(en)
|
1997-05-28 |
2006-01-10 |
Astrazeneca Ab |
Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
|
DE19754082A1
(de)
|
1997-12-05 |
1999-06-10 |
Knoll Ag |
Methode zur Bekämpfung der Fettleibigkeit
|
EP1140079B1
(en)
|
1998-12-23 |
2009-06-03 |
Glaxo Group Limited |
Assays for ligands for nuclear receptors
|
JP2002541258A
(ja)
|
1999-04-09 |
2002-12-03 |
セル セラピューティクス インコーポレーテッド |
インターリューキン−12シグナルを阻害するための治療用化合物及びその使用方法
|
CN1368975A
(zh)
|
1999-06-11 |
2002-09-11 |
阿勒根销售公司 |
具有核激素受体调节活性的有机硅化合物
|
WO2002040458A1
(fr)
|
2000-11-17 |
2002-05-23 |
Takeda Chemical Industries, Ltd. |
Derives d'isoxazole
|
MXPA03004926A
(es)
|
2001-02-14 |
2005-02-14 |
Warner Lambert Co |
Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas.
|
US20040105884A1
(en)
|
2001-04-17 |
2004-06-03 |
Ping Gao |
Pharmaceutical dosage form comprising a sulfite compound
|
US20040131670A1
(en)
|
2001-04-17 |
2004-07-08 |
Ping Gao |
Pellicle-resistant gelatin capsule
|
US20040105883A1
(en)
|
2001-04-17 |
2004-06-03 |
Ping Gao |
Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
|
US20040105885A1
(en)
|
2001-04-17 |
2004-06-03 |
Ping Gao |
Gelatin capsule exhibiting reduced cross-linking
|
US7223791B2
(en)
|
2001-06-26 |
2007-05-29 |
Takeda Pharmaceutical Company Limited |
Function regulator for retinoid relative receptor
|
US7655658B2
(en)
|
2001-08-10 |
2010-02-02 |
Palatin Technologies, Inc. |
Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
|
WO2003015777A1
(en)
|
2001-08-13 |
2003-02-27 |
Lion Bioscience Ag |
Nr1h4 nuclear receptor binding compounds
|
ATE381542T1
(de)
|
2001-08-13 |
2008-01-15 |
Phenex Pharmaceuticals Ag |
Nr1h4-kern-rezeptor-bindende verbindungen
|
US20070010562A1
(en)
|
2001-08-13 |
2007-01-11 |
Ulrike Bauer |
Nr1h4 nuclear receptor binding compounds
|
EP1478437B1
(en)
|
2002-02-27 |
2005-08-31 |
Pfizer Products Inc. |
Acc inhibitors
|
US20050107475A1
(en)
|
2002-03-21 |
2005-05-19 |
Jones Stacey A. |
Methods of using farnesoid x receptor (frx) agonists
|
US7595311B2
(en)
|
2002-05-24 |
2009-09-29 |
Exelixis, Inc. |
Azepinoindole derivatives as pharmaceutical agents
|
JP2006502134A
(ja)
|
2002-08-09 |
2006-01-19 |
アストラゼネカ アクチボラグ |
代謝調節型グルタミン酸受容体において活性を有する化合物
|
JP2006506340A
(ja)
|
2002-08-09 |
2006-02-23 |
アストラゼネカ アクチボラグ |
代謝調節型グルタミン酸受容体5のモジュレーターとしてのオキサジアゾール
|
CN1894241A
(zh)
|
2002-08-09 |
2007-01-10 |
阿斯利康(瑞典)有限公司 |
作为代谢型谷氨酸受体-5调节剂的“1,2,4” 噁二唑
|
WO2004014916A1
(en)
|
2002-08-13 |
2004-02-19 |
Warner-Lambert Company Llc |
Pyrimidine fused bicyclic metalloproteinase inhibitors
|
EP1407774A1
(en)
|
2002-09-10 |
2004-04-14 |
LION Bioscience AG |
2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
|
WO2004046162A2
(en)
|
2002-11-14 |
2004-06-03 |
The Scripps Research Institute |
Non-steroidal fxr agonists
|
US20050143449A1
(en)
|
2002-11-15 |
2005-06-30 |
The Salk Institute For Biological Studies |
Non-steroidal farnesoid X receptor modulators and methods for the use thereof
|
EP1562915A1
(en)
|
2002-11-22 |
2005-08-17 |
SmithKline Beecham Corporation |
Farnesoid x receptor agonists
|
EP1585392B1
(en)
|
2003-01-06 |
2009-03-18 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Herbicides inhibiting the action of plant acetyl-coa carboxylase for use as pesticides.
|
AU2004207706B2
(en)
|
2003-01-29 |
2010-03-04 |
Takeda Pharmaceutical Company Limited |
Thienopyrimidine compounds and use thereof
|
US20070166710A1
(en)
|
2003-03-31 |
2007-07-19 |
Markus Stoffel |
Methods for inhibiting adipogenesis and for treating type 2 diabetes
|
WO2005077345A1
(en)
|
2004-02-03 |
2005-08-25 |
Astrazeneca Ab |
Compounds for the treatment of gastro-esophageal reflux disease
|
WO2005077373A2
(en)
|
2004-02-03 |
2005-08-25 |
Astrazeneca Ab |
Treatment of gastro-esophageal reflux disease (gerd)
|
US7585881B2
(en)
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
AU2005245411B2
(en)
|
2004-05-14 |
2009-04-23 |
Irm Llc |
Compounds and compositions as PPAR modulators
|
MY144903A
(en)
|
2004-06-17 |
2011-11-30 |
Novartis Ag |
Pyrrolopyridine derivatives and their use as crth2 antagonists
|
US7947691B2
(en)
|
2004-07-21 |
2011-05-24 |
Athersys, Inc. |
Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
|
CA2583177A1
(en)
|
2004-10-13 |
2006-04-27 |
Ptc Therapeutics, Inc. |
Compounds for nonsense suppression, and methods for their use
|
JP2008137894A
(ja)
|
2005-03-22 |
2008-06-19 |
Nippon Kayaku Co Ltd |
新規なアセチレン誘導体
|
US8952176B2
(en)
|
2005-06-07 |
2015-02-10 |
Shionogi & Co., Ltd. |
Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
|
EP1963331A1
(en)
|
2005-12-15 |
2008-09-03 |
Exelixis, Inc. |
Azepinoindole derivatives as pharmaceutical agents
|
JP5081161B2
(ja)
|
2005-12-19 |
2012-11-21 |
スミスクライン ビーチャム コーポレーション |
ファルネソイドx受容体アゴニスト
|
US7560551B2
(en)
|
2006-01-23 |
2009-07-14 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
JP5301286B2
(ja)
|
2006-02-03 |
2013-09-25 |
イーライ リリー アンド カンパニー |
Fx受容体を調節するための化合物及び方法
|
AU2007215207A1
(en)
|
2006-02-14 |
2007-08-23 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
|
CA2644996A1
(en)
|
2006-03-02 |
2007-09-13 |
Cv Therapeutics, Inc. |
A2a adenosine receptor antagonists
|
JP2009531364A
(ja)
|
2006-03-28 |
2009-09-03 |
ノバルティス アクチエンゲゼルシャフト |
アミド誘導体およびgタンパク質関連疾患の処置のためのそれらの使用
|
US20090286806A1
(en)
|
2006-04-17 |
2009-11-19 |
Hassan Pajouhesh |
Isoxazole derivatives as calcium channel blockers
|
BRPI0711875A2
(pt)
|
2006-05-24 |
2012-01-10 |
Lilly Co Eli |
compostos e métodos para modular os fxr
|
DK2029547T3
(da)
|
2006-05-24 |
2010-07-26 |
Lilly Co Eli |
FXR-agonister
|
EP2029600B1
(de)
|
2006-05-24 |
2012-03-14 |
Boehringer Ingelheim International GmbH |
Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
|
US7521442B2
(en)
|
2006-05-25 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
WO2008002573A2
(en)
|
2006-06-27 |
2008-01-03 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
|
WO2008005538A2
(en)
|
2006-07-05 |
2008-01-10 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
CN101501023A
(zh)
|
2006-07-07 |
2009-08-05 |
贝林格尔.英格海姆国际有限公司 |
苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途
|
WO2008013660A2
(en)
|
2006-07-07 |
2008-01-31 |
Biostratum, Inc. |
Inhibitors of advanced glycation end products
|
EP1894928A1
(en)
|
2006-08-29 |
2008-03-05 |
PheneX Pharmaceuticals AG |
Heterocyclic fxr binding compounds
|
EP1894924A1
(en)
|
2006-08-29 |
2008-03-05 |
Phenex Pharmaceuticals AG |
Heterocyclic FXR binding compounds
|
US8193225B2
(en)
|
2006-10-13 |
2012-06-05 |
The Board Of Regents Of The University Of Texas System |
Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
|
CL2007003035A1
(es)
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
US8501933B2
(en)
|
2006-11-09 |
2013-08-06 |
Roche Palo Alto Llc |
Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
|
CN101679297B
(zh)
|
2006-12-08 |
2012-01-11 |
埃克塞利希斯股份有限公司 |
Lxr和fxr调节剂
|
GB0625842D0
(en)
|
2006-12-22 |
2007-02-07 |
Argenta Discovery Ltd |
Indolizine derivatives
|
US20090105251A1
(en)
|
2007-01-25 |
2009-04-23 |
Benjamin Jones |
Renin inhibitors
|
US7511149B2
(en)
|
2007-02-09 |
2009-03-31 |
Dow Agrosciences Llc |
Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines
|
MX2009008421A
(es)
|
2007-02-09 |
2009-11-02 |
Dow Agrosciences Llc |
Proceso para la oxidacion de ciertas sulfiliminas sustituidas a sulfoximinas insecticidas.
|
BRPI0807702B8
(pt)
|
2007-02-26 |
2022-06-28 |
Dow Agrosciences Llc |
Processo para a preparação de certas sulfiliminas substituídas
|
US8501750B2
(en)
|
2007-05-21 |
2013-08-06 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
US20100249179A1
(en)
|
2007-06-13 |
2010-09-30 |
Smithkline Beecham Corporation |
Farnesoid X Receptor Agonists
|
JP2008308448A
(ja)
|
2007-06-15 |
2008-12-25 |
Sankyo Agro Kk |
(3−硫黄原子置換フェニル)へテロアリール誘導体
|
WO2008155054A1
(en)
|
2007-06-20 |
2008-12-24 |
F. Hoffmann-La Roche Ag |
Farnesoid-x-receptor mutants, and crystallisation thereof
|
US20100240657A1
(en)
|
2007-07-02 |
2010-09-23 |
Boehringer Ingelheim International Gmbh |
Chemical compounds
|
MX2009013946A
(es)
|
2007-07-02 |
2010-03-10 |
Glaxosmithkline Llc |
Agonistas del receptor de farnesoide x.
|
US20090197880A1
(en)
|
2007-07-13 |
2009-08-06 |
Genelabs Technologies, Inc. |
Anti-viral compounds, compositions, and methods of use
|
KR20100056462A
(ko)
|
2007-07-13 |
2010-05-27 |
글락소스미스클라인 엘엘씨 |
항바이러스 화합물, 조성물 및 용도
|
TW200906823A
(en)
|
2007-07-16 |
2009-02-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
MX2010001171A
(es)
|
2007-08-01 |
2010-03-01 |
Lundbeck & Co As H |
Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sistema dopaminergico.
|
US8188080B2
(en)
|
2007-10-17 |
2012-05-29 |
Sanford-Burnham Medical Research Institute |
VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
|
US20090143451A1
(en)
|
2007-11-14 |
2009-06-04 |
Andrews William H |
Compounds that increase telomerase reverse transcriptase (tert) expression and methods for using the same
|
PE20091157A1
(es)
|
2007-12-21 |
2009-09-03 |
Astrazeneca Ab |
Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
EP2418207A1
(en)
|
2008-05-13 |
2012-02-15 |
Boehringer Ingelheim International GmbH |
Sulfone compounds which modulate the CB2 receptor
|
WO2009143150A2
(en)
|
2008-05-19 |
2009-11-26 |
Burnham Institute For Medical Research |
Intestinal alkaline phosphatase modulators and uses thereof
|
WO2009143018A2
(en)
|
2008-05-19 |
2009-11-26 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
EP2128158A1
(en)
|
2008-05-26 |
2009-12-02 |
Phenex Pharmaceuticals AG |
Heterocyclic cyclopropyl-substituted FXR binding compounds
|
AU2009257635A1
(en)
|
2008-06-10 |
2009-12-17 |
Plexxikon, Inc. |
5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
|
US8822513B2
(en)
|
2010-03-01 |
2014-09-02 |
Gtx, Inc. |
Compounds for treatment of cancer
|
US20110288114A1
(en)
|
2008-06-20 |
2011-11-24 |
Kinemed, Inc. |
Compositions for the treatment of fibrotic diseases or conditions
|
CA2727078A1
(en)
|
2008-06-23 |
2009-12-30 |
Basf Se |
Sulfoximinamide compounds for combating animal pests
|
US20100029655A1
(en)
|
2008-07-11 |
2010-02-04 |
Martin Robert Leivers |
Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them
|
US8044214B2
(en)
|
2008-08-25 |
2011-10-25 |
Angus Chemical Company |
Process for preparing isoxazole compounds
|
WO2010033906A2
(en)
|
2008-09-19 |
2010-03-25 |
President And Fellows Of Harvard College |
Efficient induction of pluripotent stem cells using small molecule compounds
|
KR101444988B1
(ko)
|
2008-09-25 |
2014-09-26 |
에프. 호프만-라 로슈 아게 |
3-아미노-인다졸 또는 3-아미노-4,5,6,7-테트라하이드로-인다졸 유도체
|
JP5425911B2
(ja)
|
2008-09-25 |
2014-02-26 |
エフ.ホフマン−ラ ロシュ アーゲー |
脂質異常症及び関連疾患に対するfxrモジュレーターとしての2,3−置換インダゾール又は4,5,6,7−テトラヒドロ−インダゾール
|
EP2334681A1
(en)
|
2008-09-26 |
2011-06-22 |
Wyeth LLC |
1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
|
NZ592603A
(en)
|
2008-10-21 |
2013-02-22 |
Metabolex Inc |
Aryl gpr120 receptor agonists and uses thereof
|
US8501804B2
(en)
|
2008-10-27 |
2013-08-06 |
Takeda Pharmaceutical Company Limited |
Bicyclic compound
|
US20100113473A1
(en)
|
2008-10-30 |
2010-05-06 |
Player Mark R |
Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
|
FR2937972B1
(fr)
|
2008-11-04 |
2013-03-29 |
Galderma Res & Dev |
Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
|
WO2010089303A1
(en)
|
2009-02-04 |
2010-08-12 |
Boehringer Ingelheim International Gmbh |
CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
|
KR20100092909A
(ko)
|
2009-02-13 |
2010-08-23 |
주식회사 엘지생명과학 |
잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물
|
FR2943059A1
(fr)
|
2009-03-16 |
2010-09-17 |
Sanofi Aventis |
Derives de n-°6-aza-bicyclo°3.2.1!oct-5-yl)-aryl-methyl!- heterobenzamide,leur preparation et leur application en therapeutique
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
US8710056B2
(en)
|
2009-07-06 |
2014-04-29 |
Basf Se |
Pyridazine compounds for controlling invertebrate pests
|
CN102469785A
(zh)
|
2009-07-24 |
2012-05-23 |
巴斯夫欧洲公司 |
防治无脊椎动物害虫的吡啶衍生物
|
US9212177B2
(en)
|
2009-08-05 |
2015-12-15 |
Versitech Limited |
Antiviral compounds and methods of making and using thereof
|
EP2289883A1
(en)
|
2009-08-19 |
2011-03-02 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
CA2771592A1
(en)
|
2009-09-04 |
2011-03-10 |
Zalicus Pharmaceuticals Ltd. |
Substituted heterocyclic derivatives for the treatment of pain and epilepsy
|
US9095596B2
(en)
|
2009-10-15 |
2015-08-04 |
Southern Research Institute |
Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
|
TWI574968B
(zh)
|
2009-12-29 |
2017-03-21 |
波克賽爾公司 |
Ampk(amp-活化蛋白激酶)活化劑及其醫療用途
|
RU2581367C2
(ru)
|
2010-03-01 |
2016-04-20 |
Джи Ти Икс, ИНК. |
Соединения для лечения рака
|
US20130231348A1
(en)
|
2010-06-09 |
2013-09-05 |
Afraxis, Inc. |
8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
|
WO2012058531A2
(en)
|
2010-10-29 |
2012-05-03 |
North Carolina State University |
Modulation of response regulators by imidazole derivatives
|
TWI408128B
(zh)
|
2010-12-03 |
2013-09-11 |
Nat Univ Tsing Hua |
間-三聯苯衍生物及其在有機發光二極體之應用
|
ES2545110T3
(es)
|
2010-12-10 |
2015-09-08 |
Rottapharm Biotech S.R.L. |
Derivados de piridinamida como antagonistas del receptor EP4
|
EP2655369A1
(en)
|
2010-12-20 |
2013-10-30 |
Irm Llc |
Compositions and methods for modulating farnesoid x receptors
|
JP2014500318A
(ja)
|
2010-12-20 |
2014-01-09 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
ファルネソイドx受容体を調節するための組成物および方法
|
CU24152B1
(es)
|
2010-12-20 |
2016-02-29 |
Irm Llc |
1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
|
WO2012090219A2
(en)
|
2010-12-31 |
2012-07-05 |
Jubilant Biosys Ltd. |
Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
|
FR2981933B1
(fr)
|
2011-11-02 |
2013-11-15 |
Galderma Res & Dev |
Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
CA2855372C
(en)
|
2011-11-11 |
2022-03-22 |
Nimbus Apollo, Inc. |
2,4-dioxo-thieno[2,3-d]pyrimidinyl derivatives and pharmaceutical compositions thereof used as acc inhibitors
|
AU2013277429B2
(en)
|
2012-06-19 |
2016-01-14 |
Intercept Pharmaceuticals, Inc. |
Preparation, uses and solid forms of obeticholic acid
|
TWI621618B
(zh)
|
2013-03-13 |
2018-04-21 |
比利時商健生藥品公司 |
經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途
|
KR101617812B1
(ko)
|
2013-04-22 |
2016-05-03 |
카딜라 핼쓰캐어 리미티드 |
비알콜성 지방간 질환을 위한 신규 조성물
|
WO2014181287A1
(en)
|
2013-05-09 |
2014-11-13 |
Piramal Enterprises Limited |
Heterocyclyl compounds and uses thereof
|
MX2015015421A
(es)
|
2013-05-10 |
2016-06-21 |
Nimbus Apollo Inc |
Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
|
US9988399B2
(en)
|
2013-05-10 |
2018-06-05 |
Gilead Apollo, Llc |
Bicyclic compounds as ACC inhibitors and uses thereof
|
BR112015028399B1
(pt)
|
2013-05-14 |
2021-11-16 |
Intercept Pharmaceuticals, Inc |
Derivados 11-hidroxila de ácidos biliares e conjugados de aminoácido dos mesmos como moduladores de receptor farnesoide x, composição farmacêutica e uso dos referidos derivados
|
TWI696462B
(zh)
|
2013-07-10 |
2020-06-21 |
日商興和股份有限公司 |
非酒精性脂肪性肝疾病治療劑
|
WO2015007451A1
(en)
|
2013-07-15 |
2015-01-22 |
Syngenta Participations Ag |
Microbiocidal heterobicyclic derivatives
|
AU2014296023B2
(en)
|
2013-08-01 |
2020-02-06 |
The Penn State Research Foundation |
Inhibitors of the farnesoid X receptor and uses in medicine
|
DK3043865T3
(da)
|
2013-09-11 |
2021-02-01 |
Univ Claude Bernard Lyon |
Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
|
US20150082981A1
(en)
|
2013-09-20 |
2015-03-26 |
E I Du Pont De Nemours And Company |
Capture of trifluoromethane using ionic liquids
|
CN104513213A
(zh)
|
2013-09-28 |
2015-04-15 |
山东亨利医药科技有限责任公司 |
Fxr激动剂
|
WO2015065983A1
(en)
|
2013-10-29 |
2015-05-07 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of gastrointestinal infections
|
RS57179B1
(sr)
|
2013-11-05 |
2018-07-31 |
Novartis Ag |
Kompozicije i postupci za modulaciju farnezoid x receptora
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
US10077268B2
(en)
|
2014-03-13 |
2018-09-18 |
Salk Institute For Biological Studies |
FXR agonists and methods for making and using
|
AU2015229055B2
(en)
|
2014-03-13 |
2019-09-12 |
Salk Institute For Biological Studies |
Analogs of fexaramine and methods of making and using
|
JP2017510572A
(ja)
|
2014-03-13 |
2017-04-13 |
ソーク インスティチュート フォー バイオロジカル スタディーズ |
Fxrアゴニストならびに作製および使用のための方法
|
TW201620899A
(zh)
|
2014-04-14 |
2016-06-16 |
歌林達有限公司 |
經雜芳基取代之雜環碸
|
WO2015162538A1
(en)
|
2014-04-21 |
2015-10-29 |
Lupin Limited |
Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
|
WO2015162244A1
(en)
|
2014-04-25 |
2015-10-29 |
Basf Se |
N-acylamidine compounds
|
WO2015165960A1
(en)
|
2014-04-30 |
2015-11-05 |
Basf Se |
N-acylamidine compounds
|
SI3626725T1
(sl)
|
2014-05-29 |
2023-04-28 |
Bar Pharmaceuticals S.R.L. |
Derivati holana za uporabo pri zdravljenju in/ali preprečevanju bolezni, posredovanih s FXR in TGR5/GPBAR1
|
CN104045635A
(zh)
|
2014-06-23 |
2014-09-17 |
华东理工大学 |
3,4,5-三取代异恶唑类化合物及其用途
|
AU2015323779B2
(en)
|
2014-09-25 |
2018-08-09 |
Astrazeneca Ab |
Combination of an omega-3 fatty acid and an SGLT-2 inhibitor for treating diseases of the liver
|
WO2016054560A1
(en)
|
2014-10-02 |
2016-04-07 |
Flatley Discovery Lab |
Isoxazole compounds and methods for the treatment of cystic fibrosis
|
EP3006939A1
(en)
|
2014-10-06 |
2016-04-13 |
Gilead Sciences, Inc. |
Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
|
JP6457069B2
(ja)
|
2014-10-27 |
2019-01-23 |
エルジー・ケム・リミテッド |
有機電界発光素子
|
MX2017005935A
(es)
|
2014-11-06 |
2018-01-11 |
Enanta Pharm Inc |
Análogos de ácido biliar como agonistas fxr/tgr5 y métodos de uso de los mismos.
|
WO2016081918A1
(en)
|
2014-11-21 |
2016-05-26 |
Akarna Therapeutics, Ltd. |
Fused bicyclic compounds for the treatment of disease
|
AU2015353473A1
(en)
|
2014-11-26 |
2017-06-08 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
WO2016086134A1
(en)
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
EP3034499A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Novel FXR (NR1H4) modulating compounds
|
EP3034501A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Hydroxy containing FXR (NR1H4) modulating compounds
|
RU2017125365A
(ru)
|
2014-12-18 |
2019-01-21 |
Новартис Аг |
Производные азабициклооктана в качестве агонистов fxr для применения при лечении заболеваний печени и желудочно-кишечных заболеваний
|
US20180021341A1
(en)
|
2015-01-09 |
2018-01-25 |
Gilead Apollo, Llc |
Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
|
CN107257793A
(zh)
|
2015-01-20 |
2017-10-17 |
梅里亚股份有限公司 |
抗蠕虫化合物、组合物及其使用方法
|
TWI698430B
(zh)
|
2015-02-13 |
2020-07-11 |
南北兄弟藥業投資有限公司 |
三環化合物及其在藥物中的應用
|
US10100285B2
(en)
|
2015-04-03 |
2018-10-16 |
Propagenix Inc. |
Ex vivo proliferation of epithelial cells
|
CN106146483A
(zh)
|
2015-04-23 |
2016-11-23 |
上海迪诺医药科技有限公司 |
杂环类法尼酯衍生物x受体调节剂
|
GB201507340D0
(en)
|
2015-04-29 |
2015-06-10 |
Univ St Andrews |
Light emitting devices and compounds
|
US20180192651A1
(en)
|
2015-07-13 |
2018-07-12 |
Vanderbilt University |
Thermal volatilization of orco agonists
|
US10066201B2
(en)
|
2015-09-11 |
2018-09-04 |
Propagenix Inc. |
Ex vivo proliferation of epithelial cells
|
AR106472A1
(es)
|
2015-10-26 |
2018-01-17 |
Gilead Apollo Llc |
Inhibidores de acc y usos de los mismos
|
KR20180082556A
(ko)
|
2015-11-25 |
2018-07-18 |
길리어드 아폴로, 엘엘씨 |
피라졸 acc 억제제 및 그의 용도
|
HUE053175T2
(hu)
|
2015-11-25 |
2021-06-28 |
Gilead Apollo Llc |
ACC-gátló észterek és azok alkalmazása
|
SI3379933T1
(sl)
|
2015-11-25 |
2023-07-31 |
Gilead Apollo, Llc |
Fungicidni sestavki, ki vsebujejo derivate 2,4-diokso-1,4-dihidrotieno (2,3-d)pirimidina
|
KR20180082557A
(ko)
|
2015-11-25 |
2018-07-18 |
길리어드 아폴로, 엘엘씨 |
트리아졸 acc 억제제 및 그의 용도
|
ES2858312T3
(es)
|
2015-12-04 |
2021-09-30 |
Bristol Myers Squibb Co |
Agonistas del receptor de apelina y métodos de uso
|
TW201734002A
(zh)
|
2015-12-11 |
2017-10-01 |
拜耳作物科學股份有限公司 |
作為殺蟲劑之經取代的丙二醯胺類
|
CN106946867B
(zh)
|
2016-01-06 |
2019-11-12 |
广州市恒诺康医药科技有限公司 |
Fxr受体调节剂及其制备方法和用途
|
EP3190103A1
(en)
|
2016-01-08 |
2017-07-12 |
Rijksuniversiteit Groningen |
Inhibitors of the pd-1/pd-l1 protein/protein interaction
|
US10882871B2
(en)
|
2016-01-10 |
2021-01-05 |
British Columbia Cancer Agency Branch |
18/19F-labelled compounds which target the prostate specific membrane antigen
|
WO2017122209A2
(en)
|
2016-01-12 |
2017-07-20 |
Yeda Research And Development Co. Ltd. |
NF-kappaB INHIBITORS
|
WO2017128896A1
(zh)
|
2016-01-26 |
2017-08-03 |
江苏豪森药业集团有限公司 |
Fxr激动剂及其制备方法和应用
|
CN107021958A
(zh)
|
2016-02-01 |
2017-08-08 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
WO2017133521A1
(zh)
|
2016-02-01 |
2017-08-10 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
CN107021957A
(zh)
|
2016-02-01 |
2017-08-08 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
TW201741307A
(zh)
|
2016-02-22 |
2017-12-01 |
艾洛斯生物製藥公司 |
Fxr調節劑及其使用方法
|
JP6944462B2
(ja)
|
2016-03-02 |
2021-10-06 |
ギリアド アポロ, エルエルシー |
チエノピリミジンジオンacc阻害剤の固体形態およびその生成のための方法
|
CN107224583A
(zh)
|
2016-03-24 |
2017-10-03 |
中美华世通生物医药科技(武汉)有限公司 |
药物组合物及其用途
|
FR3050112B1
(fr)
|
2016-04-15 |
2020-09-04 |
Soc Civ Immobiliere Gecinq |
Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
|
US10080741B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
US10080742B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
WO2017189663A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
US10149835B2
(en)
|
2016-05-18 |
2018-12-11 |
Elmore Patent Law Group, P.C. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
US10138228B2
(en)
|
2016-05-18 |
2018-11-27 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use therof
|
US10144729B2
(en)
|
2016-05-18 |
2018-12-04 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
RU2740902C2
(ru)
|
2016-06-03 |
2021-01-21 |
Хемоцентрикс, Инк. |
Способ лечения фиброза печени
|
AR108711A1
(es)
|
2016-06-13 |
2018-09-19 |
Gilead Sciences Inc |
Compuestos moduladores de fxr (nr1h4)
|
CA2968836A1
(en)
*
|
2016-06-13 |
2017-12-13 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
PL3730487T3
(pl)
|
2016-06-13 |
2022-08-16 |
Gilead Sciences, Inc. |
Pochodne azetydyny jako modulatory fxr (nr1h4)
|
SG11201809559UA
(en)
|
2016-06-13 |
2018-12-28 |
Glaxosmithkline Ip Dev Ltd |
Substituted pyridines as inhibitors of dnmt1
|
TW201808283A
(zh)
|
2016-08-05 |
2018-03-16 |
廣東東陽光藥業有限公司 |
含氮三環化合物及其在藥物中的應用
|
CN116854681A
(zh)
|
2016-08-23 |
2023-10-10 |
阿德利克斯股份有限公司 |
用于治疗代谢病状和病症的激素受体调节剂
|
US11091482B2
(en)
|
2016-08-23 |
2021-08-17 |
Ardelyx, Inc. |
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
|
CN108430998B
(zh)
|
2016-09-28 |
2021-07-09 |
四川科伦博泰生物医药股份有限公司 |
氮杂双环衍生物及其制备方法和用途
|
EP3519408A1
(en)
|
2016-09-29 |
2019-08-07 |
Bayer CropScience Aktiengesellschaft |
1 -[2-(1 -chlorocyclopropyl)-2-hydroxy-3-(3-phenyl-1,2-oxazol-5-yl)propyl]-1h-imidazole-5-carbonitrile derivatives and related compounds as fungicides for crop protection
|
RU2019113066A
(ru)
|
2016-10-04 |
2020-11-09 |
Энанта Фармасьютикалс, Инк. |
Аналоги изоксазола как агонисты fxr и способы их применения
|
WO2018075650A1
(en)
|
2016-10-18 |
2018-04-26 |
Madrigal Pharmaceuticals, Inc. |
Methods of treating liver disorders or lipid disorders with a thr-beta agonist
|
CN107973790A
(zh)
|
2016-10-22 |
2018-05-01 |
合帕吉恩治疗公司 |
杂环fxr调节剂
|
WO2018087599A1
(en)
|
2016-11-10 |
2018-05-17 |
Galmed Research And Development Ltd. |
Treatment for fibrosis
|
CA3042398A1
(en)
|
2016-11-11 |
2018-05-17 |
Gilead Sciences, Inc. |
Methods of treating liver disease
|
CN106588804B
(zh)
|
2016-12-09 |
2018-11-09 |
都创(上海)医药科技有限公司 |
一种作为类法尼醇x受体(fxr)的化合物的制备方法
|
CN106632294A
(zh)
|
2016-12-15 |
2017-05-10 |
宁波百纳西药业有限公司 |
一种螺环化合物及其药物用途
|
CN106748922B
(zh)
|
2017-01-12 |
2019-02-01 |
中国药科大学 |
一类新型砜酸衍生物、其制备方法及其作为药物的用途
|
WO2018133858A1
(en)
|
2017-01-22 |
2018-07-26 |
Sunshine Lake Pharma Co., Ltd. |
Thienopyrimidine derivative and use thereof in medicine
|
AU2018227588B2
(en)
|
2017-03-03 |
2021-01-21 |
Gilead Sciences, Inc. |
Processes for preparing ACC inhibitors and solid forms thereof
|
CN110461328A
(zh)
|
2017-03-28 |
2019-11-15 |
吉利德科学公司 |
治疗肝疾病的治疗组合
|
CN110742895A
(zh)
|
2017-03-30 |
2020-02-04 |
复旦大学附属中山医院 |
Fxr激动剂在制备治疗脂肪肉瘤药物中的用途
|
KR20190132515A
(ko)
|
2017-04-12 |
2019-11-27 |
길리애드 사이언시즈, 인코포레이티드 |
간 질환을 치료하는 방법
|
WO2018190643A1
(en)
|
2017-04-12 |
2018-10-18 |
Il Dong Pharmaceutical Co., Ltd. |
An isoxazole derivatives as nuclear receptor agonists and used thereof
|
US20210121493A1
(en)
|
2017-07-25 |
2021-04-29 |
Cedars-Sinai Medical Center |
Methods for treating liver diseases
|
KR20190036705A
(ko)
|
2017-09-28 |
2019-04-05 |
한미약품 주식회사 |
(2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체
|
KR102419458B1
(ko)
|
2017-10-06 |
2022-07-12 |
길리애드 사이언시즈, 인코포레이티드 |
Acc 억제제를 포함하는 조합 요법
|
EP3873900A1
(en)
|
2018-10-30 |
2021-09-08 |
Gilead Sciences, Inc. |
Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
|
PL3911647T3
(pl)
|
2019-01-15 |
2024-05-20 |
Gilead Sciences, Inc. |
Związek izoksazolowy jako agonista fxr oraz zawierające go kompozycje farmaceutyczne
|
CN118388474A
(zh)
|
2019-02-19 |
2024-07-26 |
吉利德科学公司 |
Fxr激动剂的固体形式
|
CN113573700A
(zh)
|
2019-03-11 |
2021-10-29 |
吉利德科学公司 |
化合物的制剂及其用途
|